Biohaven Ltd BHVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
-
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
-
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
-
Biohaven Shares Fall Premarket on Partial FDA Hold on BHV-7000
-
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
-
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
-
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
-
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Trading Information
- Previous Close Price
- $11.43
- Day Range
- $10.70–11.40
- 52-Week Range
- $7.48–18.57
- Bid/Ask
- $10.80 / $11.78
- Shares Outstanding
- 151.04M
- Market Cap
- $1.63B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 274
- Website
- https://www.biohaven.com
Valuation
|
Metric
|
BHVN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 141.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BHVN
|
|---|---|
Quick Ratio | 4.28 |
Current Ratio | 4.73 |
Interest Coverage | — |
Quick Ratio
BHVN
Profitability
|
Metric
|
BHVN
|
|---|---|
Return on Assets (Normalized) | −116.82% |
Return on Equity (Normalized) | −843.83% |
Return on Invested Capital (Normalized) | −147.14% |
Return on Assets
BHVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%##Y@# | LOCK|gtZ%s | $127B | |||
| Moderna Inc
MRNA
| LOCK|sK$ZBK | LOCK|CBx | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&<vpfN | LOCK|x^<k | $81B | |||
| argenx SE ADR
ARGX
| LOCK|>x??X# | LOCK|g@l | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|v?wFPt | LOCK|cZf | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&m<@$C! | LOCK|%Xs^ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?@!?#c?r | LOCK|$cv! | $27B | |||
| Incyte Corp
INCY
| LOCK|Z^#vY%x | LOCK|td@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&<?&gH | LOCK|<Y# | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#D%@Mm! | LOCK|Gc | $14B |
United States